2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 938

Hospitalizations in Systemic Lupus Erythematosus: A Longitudinal Study
Abstract Number: 2543

Hospitalized Bacterial Infections Among U.S. Veterans with Rheumatoid Arthritis Initiating TNF Antagonist and Newer Biologic Agents
Abstract Number: 1578

How Disease Activity Trajectories Affect the Willingness to Change Treatment
Abstract Number: 1565

How FMS Patients Become Workaholics
Abstract Number: 2235

How Important Is the Assessment of ASDAS in the Long-Term Evaluation of Disease Activity in Ankylosing Spondylitis? A Comparison with Currently Used Clinical Parameters
Abstract Number: 794

How Many Steps/Day Are Associated with a Community Level Gait Speed Among Older Adults with or At High Risk of Knee OA?
Abstract Number: 2101

How Much Can Patient Reported Outcomes Improve Among Rheumatoid Arthritis Patients Who Have a Clinical Response to Biologic Therapy but Have Not Attained Low Disease Activity?
Abstract Number: 2212

How Much Does the Spondyloarthritis Research Consortium of Canada Score of the Sacroiliac Joints Change Over a 3-Month Period in Patients On Non-Biological Treatment?
Abstract Number: 98

How to Assess Risks for Pulmonary Infection in Patients Receiving Immunosuppressive Treatment for Rheumatic Diseases? A Report From a Large-Scale Prospective Cohort Study
Abstract Number: 2188

How to Better Define Inclusion Criteria in a Large Controlled Trial in Primary Sjogren Syndrome ?
Abstract Number: 2207

How Useful Is Imaging of the Sacroiliac Joints (MRI and/or X-ray) in Patients with Possible Spondyloarthritis in the Diagnostic Work-up?
Abstract Number: 1306

How well Do Patients with Rheumatoid and Psoriatic Arthritis Tolerate Methotrexate? A Retrospective Review of Discontinuation Data From a Large UK Cohort
Abstract Number: 2345

HRES-1/RAB4-Mediated Loss of DRP1 Inhibits Mitophagy, Promotes Accumulation of Mitochondria and Serves As Target for Treatment in SLE
Abstract Number: 50

Human Chondrocyte Dedifferentiation Is Accompagnied by CD105 Endoglin Expression, ALK-1/Smad1/5 Phosphorylation and Leptin Production – Stimulation by Prednisolone and Aldosterone Through the Glucocorticoid Receptor
Abstract Number: 1820

Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Gardasil^®) and Autoimmune Disorders: Safety Assessment Using the Pharmacoepidemiologic General Research Extension System

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].